Target Information

Target General Infomation
Target ID
T23547
Former ID
TTDS00125
Target Name
Opioid receptor
Target Type
Successful
Disease Analgesia [ICD9: 338; ICD10: R52, G89]
Anxiety disorder [ICD9: 300, 311; ICD10: F32, F40-F42]
Alcohol use disorders [ICD9: 303; ICD10: F10.2]
Alcohol dependence [ICD10: F10]
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89]
Constipation [ICD9: 564; ICD10: K59.0]
Dry cough; Drug withdrawal syndrome; Ppioid type drug dependence [ICD10: R05]
Hepatitis virus infection [ICD9: 573.3; ICD10: K75.9]
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26]
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25]
Influenza A infection [ICD10: J10, J11]
Moderate to severe pain [ICD10: R52, G89]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Opioid induced adverse effect [ICD9: 304; ICD10: F11]
Obesity [ICD9: 278; ICD10: E66]
Opioid addication [ICD10: F11]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Psychotic disorders [ICD9: 290-299; ICD10: F20-F29]
Parkinson's disease [ICD9: 332; ICD10: G20]
BioChemical Class
GPCR rhodopsin
Target Validation
T23547
Drugs and Mode of Action
Drug(s) Dextropropoxyphene Drug Info Approved Pain [536942], [542582]
Ketobemidone Drug Info Approved Pain [551871]
Levorphanol Drug Info Approved Moderate to severe pain [551871]
Methadone Drug Info Approved Dry cough; Drug withdrawal syndrome; Ppioid type drug dependence [551871]
Nalmefene Drug Info Approved Opioid addication [551871]
Naltrexone Drug Info Approved Alcohol dependence [551871]
Oxymorphone Drug Info Approved Moderate to severe pain [551871]
Pentazocine Drug Info Approved Moderate to severe pain [551871]
Sufentanil Drug Info Approved Analgesia [551871]
Tilidine Drug Info Approved Pain [551871]
Dihydrocodeine Drug Info Phase 4 Cancer pain [522148], [542583]
Naltrexone Drug Info Phase 4 Human immunodeficiency virus infection [525241], [539012]
Oxymorphone Drug Info Phase 4 Pain [522753], [542100]
ALO-02 Oxycodone- naltrexone core Drug Info Phase 3 Pain [551491]
Bupropion+naltrexone Drug Info Phase 3 Obesity [532233]
Oravescent fentanyl Drug Info Phase 3 Neuropathic pain [536374]
AeroLEF Drug Info Phase 2 Pain [522487]
AZD-7268 Drug Info Phase 2 Anxiety disorder [522867], [542769]
CNSB-001 Drug Info Phase 2 Neuropathic pain [548808]
JKB-122 Drug Info Phase 2 Hepatitis virus infection [525323]
NP-2 Drug Info Phase 2 Influenza A infection [548787]
OCFENTANIL Drug Info Phase 2 Pain [531161]
Odelepran Drug Info Phase 2 Alcohol use disorders [522511]
Oxytrex Drug Info Phase 2 Pain [522403]
S-297995 Drug Info Phase 2 Opioid induced adverse effect [551683]
PTI-202 Drug Info Phase 1 Pain [548354]
SYN-1001 Drug Info Phase 1 Pain [547773]
CB-01-16 Drug Info Preclinical Constipation [548954]
Propiram fumarate Drug Info Discontinued in Phase 3 Cancer pain [545491]
CereCRIB Drug Info Discontinued in Phase 2 Pain [546394]
OxycoDex Drug Info Discontinued in Phase 2 Pain [547593]
PTI-701 Drug Info Discontinued in Phase 2 Pain [547276]
Ultramorph Drug Info Discontinued in Phase 2 Pain [547177]
BL-1827 Drug Info Discontinued in Phase 1 Cancer pain [547169]
APF-580 Drug Info Terminated Pain [548583]
EK-399 Drug Info Terminated Inflammatory disease [545666]
Org-30035 Drug Info Terminated Psychotic disorders [545339]
OX-23 Drug Info Terminated Pain [548624]
Agonist AeroLEF Drug Info [544239]
BL-1827 Drug Info [547170]
CNSB-001 Drug Info [544320]
Dextropropoxyphene Drug Info [536942]
Levorphanol Drug Info [535895]
Methadone Drug Info [537460], [537485]
Oravescent fentanyl Drug Info [536374]
SYN-1001 Drug Info [527377]
Ultramorph Drug Info [525691]
Modulator ALO-02 Oxycodone- naltrexone core Drug Info [527586]
APF-580 Drug Info [550145]
AZD-7268 Drug Info [550881]
BRIFENTANIL Drug Info [531532], [551871]
CereCRIB Drug Info [550829]
Dihydrocodeine Drug Info [526452]
EK-399 Drug Info [528069]
JKB-122 Drug Info [550158], [551871]
Ketobemidone Drug Info [534254], [551871]
OCFENTANIL Drug Info [530205], [551871]
Org-30035 Drug Info [550146]
OxycoDex Drug Info [531999]
Oxymorphone Drug Info [542100]
Oxytrex Drug Info [528981]
Propiram fumarate Drug Info [533551]
PTI-202 Drug Info [551481]
PTI-701 Drug Info [551480]
Tilidine Drug Info [527358], [551871]
Antagonist Bupropion+naltrexone Drug Info [536710]
CB-01-16 Drug Info [550566]
Cyprodine Drug Info [536285]
Nalmefene Drug Info [536742], [536928]
Naltrexone Drug Info [529288], [551871]
NP-2 Drug Info [526015]
Odelepran Drug Info [532470]
Pentazocine Drug Info [534923], [537855]
S-297995 Drug Info [551683]
Sufentanil Drug Info [537460]
References
Ref 522148ClinicalTrials.gov (NCT00547885) Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain. U.S. National Institutes of Health.
Ref 522403ClinicalTrials.gov (NCT00734461) Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse. U.S. National Institutes of Health.
Ref 522487ClinicalTrials.gov (NCT00791804) Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery. U.S. National Institutes of Health.
Ref 522511ClinicalTrials.gov (NCT00804570) A Study for the Treatment of Alcohol Dependence.. U.S. National Institutes of Health.
Ref 522753ClinicalTrials.gov (NCT00955110) Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin). U.S. National Institutes of Health.
Ref 522867ClinicalTrials.gov (NCT01020799) AZD7268 Safety and Tolerability Study. U.S. National Institutes of Health.
Ref 525241ClinicalTrials.gov (NCT02478489) Alcohol Use Disorder hOsPital Treatment Trial.
Ref 525323ClinicalTrials.gov (NCT02556372) Liver Test Study of Using JKB-122 in AIH Patients.
Ref 531161A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch. Gan To Kagaku Ryoho. 2010 Sep;37(9):1747-52.
Ref 532233A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43.
Ref 536374Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
Ref 536942Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
Ref 539012(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639).
Ref 542100(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
Ref 542582(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7593).
Ref 542583(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7594).
Ref 542769(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7824).
Ref 545339Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002901)
Ref 545491Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003460)
Ref 545666Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004080)
Ref 546394Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007886)
Ref 547169Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013581)
Ref 547177Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013632)
Ref 547276Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014737)
Ref 547593Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017613)
Ref 547773Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019167)
Ref 548354Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024906)
Ref 548583Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026787)
Ref 548624Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027164)
Ref 548787Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028817)
Ref 548808Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029018)
Ref 548954Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030751)
Ref 551491Clinical pipeline report, company report or official report of Pfizer.
Ref 551683Clinical pipeline report, company report or official report of Shionogi (2011).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 525691Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000 Feb;84(2-3):121-31.
Ref 526015Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94. Epub 2001 Mar 14.
Ref 526452Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
Ref 527358Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8. Epub 2004 Dec 15.
Ref 527377Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther. 2005 May;313(2):712-9. Epub 2005 Jan 12.
Ref 527586Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9.
Ref 528069Evaluation of the discriminative stimulus effect of an enkephalin analog, EK-399, in the rat. Nihon Yakurigaku Zasshi. 1991 Jun;97(6):361-9.
Ref 528981Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83.
Ref 529288An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
Ref 530205Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6.
Ref 531532Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J Med Chem. 1990 Oct;33(10):2876-82.
Ref 531999Differential activation of the ?-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013 Jan;168(2):375-88.
Ref 532470A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20.
Ref 533551The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. J Clin Pharmacol. 1984 Jan;24(1):35-42.
Ref 534254The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
Ref 534923Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
Ref 535895Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22. Epub 2004 Jan 23.
Ref 536285Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
Ref 536374Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
Ref 536710Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
Ref 536742Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008 Jul;32(7):1159-66.
Ref 536928Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. Epub 2008 Nov 10.
Ref 536942Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
Ref 537460mu-Opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Jun 10.
Ref 537485Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
Ref 537855Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Drugs. 1993 Sep;46(3):428-45.
Ref 542100(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
Ref 544239Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246.
Ref 544320Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
Ref 547170Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013581)
Ref 550145WO patent application no. 2010,0094,51, Long-acting injectable analgesic formulations for animals.
Ref 550146WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides.
Ref 550158WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase.
Ref 550566Clinical pipeline report, company report or official report of Cosmo.
Ref 550829US patent application no. 5,874,099, Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core.
Ref 550843CA patent application no. 212323, Method for improving gastrointestinal motility.
Ref 550881EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
Ref 551480Clinical pipeline report, company report or official report of Pain Therapeutics.
Ref 551481Clinical pipeline report, company report or official report of Pain Therapeutics, Inc.
Ref 551683Clinical pipeline report, company report or official report of Shionogi (2011).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.